Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nordic's $62m IPO reheats anti-CD37 cancer therapies

This article was originally published in Scrip

Executive Summary

In the biggest life science initial public offering on a European exchange since November 2014, Nordic Nanovector grossed NOK 500m ($62.3m) from its IPO on the Oslo stock exchange on 23 March 2015. The company raised 20% more than it had originally planned, allowing it now to reach comfortably beyond the first regulatory submission for its lead product Betalutin (177Lu-tetulomab) in non-Hodgkin's lymphoma (NHL). The IPO also potentially breathes new life into an old blood cancer target, CD37.

You may also be interested in...

Popular Nordic Nanovector Private Placement To Fund Pipeline Progress

Nordic Nanovector's oversubscribed private placing secures its freedom to target therapies for hematological cancers and compete directly with other fully funded players in the field, while remaining independent.

Gender Diversity In Pharma: Caught Between Desire And Reality

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Women In High Places: Slow Progress In Pharma

With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts